Sonosite and Mediwatch Sign Distribution and Development Agreements for Urology Market

September 02, 2004

Mediwatch to Distribute Sonosite Products to UK Urology MarketSonosite Technology to be Incorporated into Mediwatch's Prostate Assessment ProductLONDON, September 2, 2004 - Sonosite Inc. (Nasdaq: SONO), the worldwide leader in high performance, hand-carried ultrasound, announced today that Sonosite, Ltd., the Company's United Kingdom (UK) subsidiary, has entered into two distribution and supply agreements with Mediwatch Plc., (LSE:MDW.L) a leading developer, manufacturer and distributor of advanced urological primary care products for the screening, diagnosis and assessment of urological disease and disorders. Under the terms of the first agreement, Mediwatch will become an authorised distributor of Sonosite's hand-carried ultrasound systems for the UK urology market. Pursuant to the second agreement, Sonosite will supply Mediwatch with its TITAN ultrasound technology to be incorporated into Mediwatch's proprietary 'One Stop' Prostate Assessment System, which is currently under development and Mediwatch intends to market worldwide when completed. Mediwatch's 'One Stop' Prostate Assessment System is designed to provide the physician with a complete system for the diagnosis and assessment of prostate health in the clinic and will include imaging, urinalysis and blood testing capabilities. "Teaming up with Mediwatch enables Sonosite to rapidly and cost-effectively expand our presence in the highly demanding, specialized UK urology market," said Graham Cox, Sonosite Vice President, European Sales. "We believe that our high performance ultrasound technology can play a significant role in aiding physicians with the early detection and management of prostate tumours and other urological conditions. Additionally, the incorporation of Sonosite's technology into Mediwatch's new 'One Stop' Prostate Assessment System, provides the opportunity for us to establish a significant position in the worldwide urology market." "Sonosite has led the ultrasound imaging market in providing clinicians with high quality, affordable ultrasound that is designed to be easily and efficiently used in the physician's office, hospital or carried to the point-of-care," said Philip Stimpson, CEO of Mediwatch Plc. "By integrating their technology with our 'One Stop' clinical system, we can provide physicians with a total solution for assessment of prostate health."About SonositeSonosite, Inc. ( is the innovator and world leader in hand-carried ultrasound, with an installed base of more than 20,000 systems. The Company, headquartered near Seattle, Washington is represented by eight subsidiaries and a global distribution netwok in over 75 countries. Sonosite's small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The Company employs approximately 450 people worldwide.